Silk Road Medical welcomes Kevin Ballinger to its Board of Directors

– USA, CA –  Silk Road Medical, Inc. (NASDAQ: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the appointment of Kevin Ballinger to its Board of Directors, effective immediately.

“We are delighted to welcome Kevin to our Board of Directors. Kevin brings extensive strategic leadership experience in the medical device industry, with a proven track record of successfully building and growing businesses,” said CEO, Erica Rogers. “His guidance will be instrumental as we look toward significant growth and operational expansion at Silk Road Medical.”

The company also announced the immediate resignation of Ruoxi Chen from the Board.

About Kevin Ballinger

Kevin Ballinger, the recently appointed CEO of Aldevron, brings decades of experience in the medical device industry. Prior to joining Aldevron, he spent 25 years at Boston Scientific, a company focused on a variety of interventional medical specialties. During his last nine years at Boston Scientific, he served as EVP and Global President of the Interventional Cardiology division. Under his leadership, Ballinger grew the division to a $3 billion global business.

“Silk Road Medical has established itself as a leader in the treatment of carotid artery disease with its revolutionary transcarotid access and neuroprotection products,” said Kevin Ballinger. “I am excited about the future prospects of the company and look forward to working together as we continue to build a world class organization. I am thrilled to be joining such a dedicated team that is at the forefront of innovation.”

Ballinger earned his BS in Mechanical Engineering from Michigan Technological University, and his MBA from the University of Minnesota’s Carlson School of Management.

About Silk Road Medical

Silk Road Medical, Inc. is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization. TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke.

For more information : https://silkroadmed.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team